Product image of Maymetsi (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Maymetsi

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Maymetsi (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride / Sitagliptin, the active ingredient in Maymetsi, is a Biguanide / DPP-4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults.
GNH India supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Maymetsi is an oral antidiabetic medication used to improve glycaemic control in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • Inadequate control on metformin alone: provides additional glucose‑lowering effect when metformin monotherapy is insufficient.
  • Combination therapy: used together with insulin or other oral agents to achieve target HbA1c levels.

How It Works

  • Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4, prolonging the activity of incretin hormones (GLP‑1 and GIP). The combined actions increase insulin secretion, decrease glucagon release, and improve overall glucose utilization without causing insulin resistance.

Side Effects

Adverse reactions may occur with any antidiabetic therapy and should be monitored.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Mild hypoglycaemia: especially when combined with insulin or sulfonylureas.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Severe hypoglycaemia: can lead to loss of consciousness.
  • Pancreatitis: acute inflammation of the pancreas.
  • Allergic reactions: rash, pruritus, or angio‑edema.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

Before initiating Maymetsi, clinicians should evaluate patient‑specific risk factors and monitor regularly.

  • Renal function: assess eGFR and avoid use in severe renal impairment.
  • Lactic acidosis risk: contraindicated in patients with significant hepatic disease.
  • Hypoglycaemia risk: monitor closely when used with insulin or sulfonylureas.
  • Cardiovascular disease: use with caution in unstable heart conditions.
  • Pregnancy and lactation: weigh benefits against potential risks; consult prescriber.
  • Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Avoid Interactions

Maymetsi may interact with several drug classes, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of severe hypoglycaemia.
  • Iodinated contrast agents: may precipitate renal dysfunction with metformin.
  • Cimetidine: can raise metformin plasma concentrations.
  • Rifampicin: reduces sitagliptin exposure, diminishing efficacy.
  • Alcohol: may potentiate lactic acidosis.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may mask hypoglycaemia symptoms.
  • Diuretics: affect renal clearance of metformin.
  • ACE inhibitors: require renal function monitoring.
  • Warfarin: possible alteration of INR values.
  • Corticosteroids: may increase blood glucose levels.

Frequently Asked Questions

Maymetsi is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It combines metformin, which lowers hepatic glucose production, with sitagliptin, which enhances insulin secretion through incretin hormone modulation.

Metformin decreases liver‑derived glucose and increases insulin sensitivity in muscle and fat tissue. Sitagliptin blocks the enzyme DPP‑4, extending the action of incretin hormones that stimulate insulin release and suppress glucagon, together providing complementary glucose‑lowering effects.

The specific dose of Maymetsi is determined by the prescribing clinician based on the patient’s renal function, glycaemic targets, and concomitant therapies. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To request Maymetsi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maymetsi offers a dual mechanism by combining a biguanide (metformin) with a DPP‑4 inhibitor (sitagliptin), providing both insulin‑sensitising and insulin‑secretagogue effects. This can be advantageous over monotherapy agents that act through a single pathway, especially when tighter glycaemic control is needed.

Maymetsi should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Maymetsi is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition, and severe hypoglycaemia when used with insulin or sulfonylureas. Patients should be educated on early signs and seek immediate medical attention if they occur.

Maymetsi is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals with uncontrolled heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT